NASDAQ$IART
Integra LifeSciences Holdings Corporation · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Integra LifeSciences' second quarter results for 2020 were reported, showing a decrease in revenue compared to the previous year due to the impact of COVID-19.
Integra LifeSciences reported a decrease in revenue of 32.6% compared to the prior year, with a GAAP loss per diluted share of ($0.00). The company's full-year 2020 guidance remains withdrawn due to the uncertainty related to COVID-19.
- Reported revenues were $258.7 million, a decrease of 32.6% on a reported basis and 31.3% on an organic basis compared to the prior year.
- GAAP loss per diluted share was ($0.00), compared to GAAP earnings of $0.34 in the second quarter of 2019.
- Adjusted earnings per diluted share were $0.33, compared to $0.73 in the prior year, with the decline largely attributable to lower revenues due to the impact of COVID-19.
- The Company's full-year 2020 guidance remains withdrawn due to the uncertainty related to COVID-19 and the extent of the recovery in surgical procedure volumes.
Headline financials
Revenue & EPS history
Integra LifeSciences · Revenue · Quarterly
$259M
Revenue by segment
Integra LifeSciences · $248M total across 4 segments · Q2 2020
- Neurosurgery$141M-26.7%57.1%
- Wound Reconstruction and Care$56.3M-31.6%22.7%
- Instruments$28.3M-49.7%11.5%
- Private Label$21.4M-29.4%8.7%
Forward guidance
The Company continues to expect quarterly sequential revenue improvement in the second half of 2020 as compared to the second quarter of 2020. For the third quarter of 2020, revenues are expected to remain below prior year levels due to COVID-19 and the associated reduction of non-emergent surgical procedures.
Tailwinds
- Expect quarterly sequential revenue improvement in the second half of 2020 as compared to the second quarter of 2020.
Headwinds
- Revenues are expected to remain below prior year levels due to COVID-19 and the associated reduction of non-emergent surgical procedures.
- The Company does not expect all markets and product lines to improve at the same rate.
- The level and location of COVID-19 emergence or recurrence and its associated impact on surgical procedure volumes, as well as economic normalization, will shape the Company's recovery.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
-0.2%
Avg return
Earnings day
-1.4%
Avg return
5 days after
-1.8%
Avg return
30 days after
51%
35 / 68 earnings
Positive
+29.2%
Q3 2024
Best reaction
-23.5%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +24.4% | +31.0% | +65.1% | |
| Q4 2025 | -2.1% | -8.9% | -20.6% | |
| Q3 2025 | -23.5% | -26.8% | -15.0% | |
| Q1 2025 | -20.9% | -27.3% | -22.3% | |
| Q4 2024 | +12.1% | +5.3% | -0.2% | |
| Q3 2024 | +29.2% | +28.5% | +25.1% | |
| Q2 2024 | -20.4% | -23.5% | -35.3% | |
| Q1 2024 | -13.2% | -10.0% | +9.9% | |
| Q4 2023 | -16.6% | -18.8% | -19.9% | |
| Q3 2023 | -4.5% | -5.8% | +6.3% | |
| Q2 2023 | -3.1% | -1.1% | -9.5% | |
| Q1 2023 | -6.2% | -5.5% | -34.7% | |
| Q4 2022 | +0.2% | +0.8% | -3.1% | |
| Q3 2022 | +11.1% | +12.7% | +21.1% | |
| Q2 2022 | -1.5% | -0.5% | -14.8% | |
| Q1 2022 | +2.9% | -0.2% | +2.5% | |
| Q4 2021 | +0.9% | +2.6% | -2.8% | |
| Q3 2021 | +7.1% | +7.5% | -5.3% | |
| Q2 2021 | -0.2% | -0.3% | +2.6% | |
| Q1 2021 | -2.0% | -3.4% | -9.9% | |
| Q4 2020 | -4.1% | -2.8% | -6.2% | |
| Q3 2020 | -7.0% | -4.5% | +19.5% | |
| Q2 2020 | +6.4% | +6.6% | -5.6% | |
| Q1 2020 | +1.5% | -2.8% | +7.9% | |
| Q4 2019 | +2.9% | -0.3% | -35.7% | |
| Q3 2019 | -7.7% | -5.1% | -2.0% | |
| Q2 2019 | +12.0% | +14.5% | +8.0% | |
| Q1 2019 | -3.1% | -2.3% | -7.7% | |
| Q4 2018 | +5.7% | +6.1% | +6.5% | |
| Q3 2018 | -12.6% | -13.5% | -13.9% | |
| Q2 2018 | -2.3% | -2.3% | -5.5% | |
| Q1 2018 | +9.8% | +12.7% | +16.7% | |
| Q4 2017 | -4.1% | -4.1% | +0.7% | |
| Q3 2017 | -9.1% | -8.2% | -4.9% | |
| Q2 2017 | -9.9% | -10.7% | -10.9% | |
| Q1 2017 | +4.6% | +5.1% | +12.1% | |
| Q4 2016 | -2.1% | -1.2% | -1.2% | |
| Q3 2016 | +1.6% | -3.4% | +3.8% | |
| Q2 2016 | +6.8% | +6.4% | +9.0% | |
| Q1 2016 | +6.7% | — | — | |
| Q4 2015 | +3.8% | — | — | |
| Q3 2015 | +2.8% | — | — | |
| Q2 2015 | -0.1% | — | — | |
| Q1 2015 | +7.5% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | -7.5% | — | — | |
| Q2 2014 | +1.0% | — | — | |
| Q1 2014 | -1.6% | — | — | |
| Q4 2013 | -3.9% | — | — | |
| Q3 2013 | +4.4% | — | — | |
| Q2 2013 | -2.2% | — | — | |
| Q1 2013 | +0.2% | — | — | |
| Q4 2012 | -4.8% | — | — | |
| Q3 2012 | -0.3% | — | — | |
| Q2 2012 | +4.1% | — | — | |
| Q1 2012 | +9.4% | — | — | |
| Q4 2011 | +1.2% | — | — | |
| Q3 2011 | -21.8% | — | — | |
| Q2 2011 | -5.3% | — | — | |
| Q1 2010 | +2.1% | — | — | |
| Q1 2011 | +0.8% | — | — | |
| Q4 2008 | -0.7% | — | — | |
| Q4 2010 | -0.7% | — | — | |
| Q3 2010 | +2.2% | — | — | |
| Q3 2009 | +2.2% | — | — | |
| Q2 2009 | +6.2% | — | — | |
| Q2 2010 | +6.2% | — | — | |
| Q4 2009 | +6.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro